A. Mark Fendrick, MD, professor of Medicine in the School of Medicine, professor of Health Management and Policy in the School of Public Health, and director of the VBID Center at the University of Michigan, discusses how low or no cost sharing for high-value services is particularly important for public health issues or epidemics, such as HIV.
A. Mark Fendrick, MD, professor of Medicine in the School of Medicine, professor of Health Management and Policy in the School of Public Health, and director of the VBID Center at the University of Michigan, discusses how low or no cost sharing for high-value services is particularly important for public health issues or epidemics, such as HIV.
How is low/no cost sharing for high-value services particularly important for public health issues or epidemics, such as HIV, where there is often access issues for those affected?
My mother always said, “I can’t believe you had to spend $1 million to show that if you make people pay more for something they’ll buy less of it,” and as we move through value-based insurance design, now almost on 20 years, we’ve also shown that if we reduce barriers—financial and otherwise—to high-value care, people will use more of these services more often. It’s important to note that when you make something free, it doesn’t mean that 100% of the people who should be getting the care, whether it be HIV testing or PrEP [pre-exposure prophylaxis] or mammograms or hepatitis C screening, to 100%.
We do know that as we’ve studied the evaluations of decreased cost sharing for high-value services, the rates of these services go up. But, they go up in a modest way. They don’t get anywhere near where I’d hope, meaning that we need not only cost-sharing reform but healthcare literacy issues, access, and many other levers we think we should pull to ultimately spend more money to get more folks the services we know will make them healthier. And the way we figured out to pay for these efforts is to attack the estimated $1 trillion in healthcare spending in the US that doesn’t make Americans any healthier.
It’s very fortunate for me and maybe unfortunate for the payers that there is such an excess of low-value care in this country. And luckily enough for us, everyone agrees there’s enough money in the system, we just spend it in the wrong places, and hopefully we’ll spend more on preventive care services like those covered by Section 2713 and HIV screening and PrEP, specifically, and less hopefully on those low-value services that have been identified by the task force as D rated or those identified by the Choosing Wisely Campaign.
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back
March 13th 2025As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More